The 53rd annual meeting of the American Society of Hematology (ASH) was held from Saturday, December 10, through Tuesday, December 13, in San Diego.
Over 20,000 people are expected to attend this year’s meeting, where experts from around the world gather to discuss current research regarding the diagnosis and treatment of various blood diseases, including multiple myeloma.
The ASH meeting is one of three annual scientific meetings where important new myeloma-related research findings are usually reported. The other two key conferences are the annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA).
Of these three meetings, “ASH” – as it is often called – is generally viewed as the most important for myeloma researchers, patients, and caregivers. This is due both to the volume and the importance of the research usually presented at the meeting.
This year’s meeting will host nearly 400 presentations and poster summaries of research focused on myeloma.
The Myeloma Beacon (myelomabeacon.com) have an extensive coverage of the papers that are presented and we will try and present some abstracts. If you are interested in reading about the extensive research I recommend you viewing their website.